drugset / Trial / NCT02938949
Alirocumab in Patients With Acute Myocardial Infarction
Phase 4
Completed
20 enrolled
Virginia Commonwealth University
Regeneron Pharmaceuticals · collabSanofi · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
Phase IV investigator initiated clinical trial to study the effectiveness of alirocumab, an inhibitor of proprotein convertase subtilisin/kexin (PCSK9), versus placebo added to high-intensity statin (atorvastatin 80 mg) in lowering low density lipoprotein (LDL) cholesterol during non-ST segment elevation myocardial infarction (NSTEMI).
Timeline
- Start
- 2017-01
- Primary completion
- 2018-08
- Completion
- 2018-08-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Alirocumab | Monoclonal antibody | 150 mg | Subcutaneous |